secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001213900-24-094344
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals appoints Vinay Shah as CFO effective Nov 16, 2024; Joseph Truluck resigns
--------------------------------------------------------------------------------

- CFO Joseph Truluck resigns effective Nov 15, 2024; will serve as consultant through Mar 31, 2025.
- Vinay Shah appointed CFO effective Nov 16, 2024, with a 3-year employment term.
- Shah receives $315K annual base salary, up to 30% discretionary bonus, and 40,000 stock options.
- Shah previously served as CFO at Virpax (VRPX) and Aravive (ARAV), with over 25 years industry experience.
- Truluck's resignation was not due to any disagreement with the company over operations or accounting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024094344/0001213900-24-094344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024094344/ea0219983-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-094344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer